Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTeijin compound 1 is a potent chemokine CCR2b receptor antagonist (IC50 = 180 nM). Potently inhibits cell chemotaxis induced by MCP-1 (EC50 = 24 nM).
分子量 | 476.32 |
公式 | C21H21ClF3N3O2.HCl |
储存 | Desiccate at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1313730-14-1 |
PubChem ID | 56972239 |
InChI Key | PGUQBBISBKGQDC-GMUIIQOCSA-N |
Smiles | O=C(CNC(C3=CC=CC(C(F)(F)F)=C3)=O)N[C@@H]1CCN(CC2=CC=C(Cl)C=C2)C1.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Hall et al (2009) Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol.Pharmacol. 75 1325 PMID: 19297521
Moree et al (2004) Small molecule antagonists of the CCR2b receptor. Part 2: discovery process and initial structure-activity relationships of diamine derivatives. Bioorg.Med.Chem.Letts. 14 5413
Moree et al (2008) Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. Bioorg.Med.Chem.Letts. 18 1869
关键词: Teijin compound 1, Teijin compound 1 supplier, Potent, CCR2b, antagonists, chemokines, receptors, Teijin, compound1, Chemokine, CC, Receptors, 3664, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Teijin compound 1 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.